GlassScriptPhysician profile
Aman B Ali
NPI 1245642255
$44,810.61
in general payments reported to CMS, 2019-2025
29 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what 80% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $56.33 · 2021: $773 · 2022: $17K · 2023: $6,145 · 2024: $19K · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Travel and Lodging: $7,124 · Food and Beverage: $6,345 · Education: $1,037 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,978.78 |
| Travel and Lodging | $7,123.95 |
| Food and Beverage | $6,344.78 |
| Education | $1,037.10 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $13,046.22 | 2023-2024 | Harmonic, Enseal, Echelon Flex |
| Ethicon US, LLC | $11,864.11 | 2020-2025 | Harmonic, Enseal, Linx Reflux Management System |
| Intuitive Surgical, INC. | $7,336.30 | 2019-2024 | Davinci Xi, Da Vinci Surgical System |
| Medical Device Business Services, INC. | $3,463.75 | 2021-2025 | Linx Reflux Management System, Echelon Flex |
| Medtronic, INC. | $2,597.60 | 2022-2025 | Ligasure, Signia, Eea |
| Boston Scientific Corporation | $2,018.42 | 2021-2025 | Apollo Esg Nxt System, Spyglass Discover, Overstitch Endoscopic Suturing System |
| Olympus Corporation of The Americas | $1,395.58 | 2022 | |
| Novo Nordisk INC | $682.63 | 2023-2025 | Wegovy, Saxenda |
| Karl Storz Endoscopy-America | $625.24 | 2023 | Image 1 S |
| Stryker Corporation | $480.61 | 2023 | 1688 |
| Allergan, INC. | $257.72 | 2019-2021 | |
| Davol INC. | $189.73 | 2022-2023 | Phasix Mesh |
| Tela Bio, INC. | $179.27 | 2023-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Olympus America INC. | $133.43 | 2023 | 4k Cable 8.5m |
| Hologic Sales and Service, LLC | $106.17 | 2025 | Coolseal Generator |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $67.56 | 2022-2023 | Gattex |
| Alafair Biosciences, INC. | $53.05 | 2023 | Versawrap |
| Lilly USA, LLC | $48.79 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $45.67 | 2024 | Andexxa |
| Teleflex LLC | $28.48 | 2024 | Titan Sgs |
| Madrigal Pharmaceuticals | $26.72 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $25.09 | 2024 | Voquezna |
| Veran Medical Technologies, INC. | $24.49 | 2020 | |
| Braintree Laboratories, INC. | $22.32 | 2023 | Sutab |
| Bsn Medical INC | $20.15 | 2019 | |
| Abbott Laboratories | $18.50 | 2025 | Mitraclip |
| Abbvie INC. | $18.32 | 2021 | |
| Currax Pharmaceuticals LLC | $17.59 | 2025 | Contrave |
| Eisai INC. | $17.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.